港股异动 | 基石药业-B(02616)现涨超4% 普吉华获纳入国家医保目录 非执行董事近日增持100万股

Group 1 - The core viewpoint of the article is that 基石药业-B (02616) has seen a stock price increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD [1] - 基石药业's drug, 普吉华 (普拉替尼胶囊, 100 mg), has been included in the latest National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration, which will take effect on January 1, 2026 [1] - On December 4, the non-executive director 胡正国 increased his holdings in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, bringing his total holdings to 3.471 million shares, representing 0.24% of the company [1]